British Journal of Haematology · 2015 · 21 citations · 28 references
MedicinePharmacologyPharmacotherapyHematologic OncologyStem Cell TransplantationTransplant PharmacotherapyBone Marrow Transplant PharmacotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyHematopoietic Stem Cell Transplant PharmacotherapyHematopoietic Stem Cell TransplantationMaintenance TherapyAutologous Transplant PharmacotherapyDose Escalation TherapyLenalidomide TherapyMaintenance Combination TherapyMaintenance Therapy After TransplantMultiple Myeloma TherapyMultiple Myeloma TreatmentTransplantation For Hematologic Malignancies
UNLABELLED: Single-agent post-autologous transplant maintenance therapy with lenalidomide is standard of care for patients with multiple myeloma. The tolerability and effectiveness of combination post-transplant maintenance therapy is unknown, so we investigated lenalidomide and vorinostat (suberoylanilide hydroxamic acid) in this setting, hypothesizing that the regimen would be well tolerated and associated with an improved post-transplant response. This trial followed a standard 3 × 3 dose escalation phase 1 design. Vorinostat was administered beginning day +90 post-haematopoietic stem cell transplantation for days 1-7 and 15-21, and lenalidomide was started at 10 mg days 1-21, both on a 28-d cycle. The primary endpoint was maximum tolerated dose and dose limiting toxicities were assessed during the first cycle. Treatment was well tolerated in 16 enrolled patients. During Cycle 1, the most common toxicities included cytopenias, gastrointestinal complaints and fatigue. Seven patients improved their transplant response after starting combination therapy. The median follow-up was 38·4 months, and the median progression-free survival and overall survival have yet to be reached. This oral post-transplant maintenance regimen was well tolerated. This is the first trial to publish results on the use of a histone deacetylase inhibitor in the maintenance setting, and it provides rationale for the ongoing randomized trial in maintenance (ISRCTN 49407852). TRIAL REGISTRATION: NCT00729118.
28
The rapid assessment of fatigue severity in cancer patients
Tito R. Mendoza, X. Shelley Wang, Charles S. Cleeland et al. · Cancer · 1999 · 1.8K citations · Full text
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal, Valérie Lauwers‐Cancès, Gérald Marit et al. · New England Journal of Medicine · 2012 · 1.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +13
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister et al. · New England Journal of Medicine · 2012 · 1.1K citations · Full text